News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pierre Fabre Obtains European Commission Marketing Authorization For Hemangiol®, The First And Only Drug Approved For The Treatment Of Proliferating Infantile Hemangioma


5/5/2014 9:05:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CASTRES, France--(BUSINESS WIRE)--Pierre Fabre Dermatologie Laboratories have obtained European Commission authorization to market Hemangiol® (propranolol), the first and only drug to be approved for the treatment of “proliferating infantile hemangioma requiring systemic treatment”. Hemangiol® is an oral solution specially developed for pediatric use. It will be launched firstly in France and Germany, and gradually throughout other European markets.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES